# Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants

> **NCT07646548** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Dupilumab coformulated with berahyaluronidase alfa
- **BIOLOGICAL:** Dupilumab

## Key facts

- **NCT ID:** NCT07646548
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-11
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646548, "Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*